Vendu! Weeks after Sanofi cuts ties to Alnylam, the pharma giant offloads $842M of its stock
Sanofi has cut its last remaining link with Alnylam, 5 years after the two first began their collaboration and just weeks since the Boston biotech told investors that they were formally ending the partnership.
A spokesperson for Alnylam says they were told last night that Sanofi $SNY had sold off its chunk of shares acquired when they partnered up, reportedly for $80.25 a share. Morgan Stanley acquired the stock.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
